Published in Semin Oncol on October 01, 2010
Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol (2013) 4.72
PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors. J Clin Invest (2014) 3.54
Immune microenvironments in solid tumors: new targets for therapy. Genes Dev (2011) 2.08
CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor. Clin Cancer Res (2013) 1.90
Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer. Cancer Res (2013) 1.78
Loss of the signaling adaptor TRAF1 causes CD8+ T cell dysregulation during human and murine chronic infection. J Exp Med (2011) 1.60
Advances in targeting cell surface signalling molecules for immune modulation. Nat Rev Drug Discov (2013) 1.46
Upregulation of circulating PD-L1/PD-1 is associated with poor post-cryoablation prognosis in patients with HBV-related hepatocellular carcinoma. PLoS One (2011) 1.38
Cancer immunotherapy: the beginning of the end of cancer? BMC Med (2016) 1.32
The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment. J Transl Med (2013) 1.31
Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy. Yale J Biol Med (2011) 1.23
Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology (2014) 1.22
Modulation of GITR for cancer immunotherapy. Curr Opin Immunol (2012) 1.17
Induced and natural regulatory T cells in human cancer. Expert Opin Biol Ther (2012) 1.15
Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA. Haematologica (2012) 1.11
B7-H3 associated with tumor progression and epigenetic regulatory activity in cutaneous melanoma. J Invest Dermatol (2013) 1.07
Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy. ISRN Oncol (2013) 1.04
NK cells and cancer: you can teach innate cells new tricks. Nat Rev Cancer (2015) 1.04
Localized immunotherapy via liposome-anchored Anti-CD137 + IL-2 prevents lethal toxicity and elicits local and systemic antitumor immunity. Cancer Res (2013) 1.04
Long-lasting complete regression of established mouse tumors by counteracting Th2 inflammation. J Immunother (2013) 1.04
Combinatorial PD-1 blockade and CD137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatin. PLoS One (2013) 1.04
Interleukin-7 and immune reconstitution in cancer patients: a new paradigm for dramatically increasing overall survival. Target Oncol (2012) 0.98
4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity. Front Oncol (2015) 0.97
Immunotherapy targets in pediatric cancer. Front Oncol (2012) 0.97
Immunotherapeutic synergy between anti-CD137 mAb and intratumoral administration of a cytopathic Semliki Forest virus encoding IL-12. Mol Ther (2012) 0.96
Targeting costimulatory molecules to improve antitumor immunity. J Biomed Biotechnol (2012) 0.96
Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer. J Transl Med (2013) 0.94
Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies. Clin Cancer Res (2014) 0.94
Emerging antibody combinations in oncology. MAbs (2011) 0.94
TNF and TNF receptor superfamily members in HIV infection: new cellular targets for therapy? Mediators Inflamm (2013) 0.93
Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander". Toxins (Basel) (2014) 0.92
Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go. Front Immunol (2013) 0.90
Emerging Opportunities and Challenges in Cancer Immunotherapy. Clin Cancer Res (2016) 0.89
Immunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137. Clin Pharmacol (2013) 0.89
Galectin-9 controls the therapeutic activity of 4-1BB-targeting antibodies. J Exp Med (2014) 0.89
A series of Fas receptor agonist antibodies that demonstrate an inverse correlation between affinity and potency. Cell Death Differ (2012) 0.88
Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells. Oncoimmunology (2015) 0.88
PD-L1 Expression Is Associated with Tumor FOXP3(+) Regulatory T-Cell Infiltration of Breast Cancer and Poor Prognosis of Patient. J Cancer (2016) 0.88
Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy. J Immunother Cancer (2014) 0.87
Genome-wide RNAi screen in IFN-γ-treated human macrophages identifies genes mediating resistance to the intracellular pathogen Francisella tularensis. PLoS One (2012) 0.85
Tumor infiltrating lymphocytes in ovarian cancer. Cancer Biol Ther (2015) 0.85
CD134/CD137 dual costimulation-elicited IFN-γ maximizes effector T-cell function but limits Treg expansion. Immunol Cell Biol (2013) 0.84
Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies. Cancer J (2013) 0.84
Immuno-oncology combinations: raising the tail of the survival curve. Cancer Biol Med (2016) 0.84
Virotherapy, gene transfer and immunostimulatory monoclonal antibodies. Oncoimmunology (2012) 0.83
The delicate balance of melanoma immunotherapy. Clin Transl Immunology (2013) 0.83
Human and mouse CD137 have predominantly different binding CRDs to their respective ligands. PLoS One (2014) 0.82
Betting on improved cancer immunotherapy by doubling down on CD134 and CD137 co-stimulation. Oncoimmunology (2013) 0.82
Locally advanced lung cancer: an optimal setting for vaccines and other immunotherapies. Cancer J (2013) 0.82
4-1BB agonism: adding the accelerator to cancer immunotherapy. Cancer Immunol Immunother (2016) 0.81
Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1. Immunotherapy (2015) 0.81
The TNF Receptor Superfamily in Co-stimulating and Co-inhibitory Responses. Immunity (2016) 0.81
Autoimmune therapies targeting costimulation and emerging trends in multivalent therapeutics. Ther Deliv (2011) 0.81
CD137 and CD137L signals are main drivers of type 1, cell-mediated immune responses. Oncoimmunology (2015) 0.81
Essential complicity of perforin-granzyme and FAS-L mechanisms to achieve tumor rejection following treatment with anti-CD137 mAb. J Immunother Cancer (2013) 0.81
Eomesodermin is required for antitumor immunity mediated by 4-1BB-agonist immunotherapy. Oncoimmunology (2014) 0.81
Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS Sites. Front Oncol (2015) 0.79
Dual targeting of CD137 co-stimulatory and PD-1 co-inhibitory molecules for ovarian cancer immunotherapy. Oncoimmunology (2014) 0.79
Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination. Front Immunol (2016) 0.78
New Strategies in Bladder Cancer: A Second Coming for Immunotherapy. Clin Cancer Res (2015) 0.78
Immunotherapy in pediatric malignancies: current status and future perspectives. Future Oncol (2014) 0.78
Combination immunotherapy: a road map. J Immunother Cancer (2017) 0.77
Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy. Front Oncol (2016) 0.77
The use of epidermal growth factor receptor monoclonal antibodies in squamous cell carcinoma of the head and neck. Chemother Res Pract (2012) 0.77
Loss of intraepidermal nerve fiber density during SIV peripheral neuropathy is mediated by monocyte activation and elevated monocyte chemotactic proteins. J Neuroinflammation (2015) 0.77
IgG4 subclass-specific responses to Staphylococcus aureus antigens shed new light on host-pathogen interaction. Infect Immun (2014) 0.77
Targeting TLR-4 with a novel pharmaceutical grade plant derived agonist, Immunomax®, as a therapeutic strategy for metastatic breast cancer. J Transl Med (2014) 0.77
Melanoma immunotherapy. Cancer Biol Ther (2014) 0.76
Finding a needle in a haystack: Activation-induced CD137 expression accurately identifies naturally occurring tumor-reactive T cells in cancer patients. Oncoimmunology (2013) 0.76
Enhanced Cytotoxic CD8 T Cell Priming Using Dendritic Cell-Expressing Human Papillomavirus-16 E6/E7-p16INK4 Fusion Protein with Sequenced Anti-Programmed Death-1. J Immunol (2016) 0.76
Delivering safer immunotherapies for cancer. Adv Drug Deliv Rev (2017) 0.76
Functional expression of CD137 (4-1BB) on T helper follicular cells. Oncoimmunology (2015) 0.75
Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too? Expert Opin Biol Ther (2016) 0.75
Obesity and cancer immunotherapy toxicity. Immunotherapy (2015) 0.75
Advancing targeted co-stimulation with antibody-fusion proteins by introducing TNF superfamily members in a single-chain format. Oncoimmunology (2016) 0.75
Tumor-Unrelated CD4 T Cell Help Augments CD134 plus CD137 Dual Costimulation Tumor Therapy. J Immunol (2015) 0.75
CD137-CRDI is not necessary in the role of contacting its natural ligand. Immunol Cell Biol (2016) 0.75
Effector function of CTLs is increased by irradiated colorectal tumor cells that modulate OX-40L and 4-1BBL and is reversed following dual blockade. BMC Res Notes (2016) 0.75
Cytokine release assays for the prediction of therapeutic mAb safety in first-in man trials--Whole blood cytokine release assays are poorly predictive for TGN1412 cytokine storm. J Immunol Methods (2015) 0.75
Anti-CD137 enhances anti-CD20 therapy of systemic B-cell lymphoma with altered immune homeostasis but negligible toxicity. Oncoimmunology (2016) 0.75
Human genetic evidence for involvement of CD137 in atherosclerosis. Mol Med (2014) 0.75
New Immunotherapy Strategies in Breast Cancer. Int J Environ Res Public Health (2017) 0.75
Cytokines and metabolic factors regulate tumoricidal T-cell function during cancer immunotherapy. Immunotherapy (2017) 0.75
Tumor-targeted costimulation by using bi-specific aptamers. Cancer Cell Microenviron (2016) 0.75
Predictors of responses to immune checkpoint blockade in advanced melanoma. Nat Commun (2017) 0.75
TNF-receptor superfamily agonists as molecular adjuvants for cancer vaccines. Curr Opin Immunol (2017) 0.75
Exploring Synergy in Combinations of Tumor-Derived Vaccines That Harbor 4-1BBL, OX40L, and GM-CSF. Front Immunol (2017) 0.75
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 17.53
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 9.86
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet (2012) 7.00
Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol (2013) 5.43
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol (2012) 5.32
Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood (2009) 5.21
PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res (2010) 4.50
Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol (2002) 4.15
Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol (2004) 3.95
The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell (2010) 3.52
Adaptive immune cells temper initial innate responses. Nat Med (2007) 3.37
The aryl hydrocarbon receptor regulates gut immunity through modulation of innate lymphoid cells. Immunity (2011) 3.32
Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J Exp Med (2007) 3.15
Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest (2014) 3.06
Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med (2005) 3.01
A clinical development paradigm for cancer vaccines and related biologics. J Immunother (2007) 2.97
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci U S A (2011) 2.90
Recognition of host immune activation by Pseudomonas aeruginosa. Science (2005) 2.84
Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J Natl Cancer Inst (2006) 2.69
Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. J Transl Med (2010) 2.65
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol (2013) 2.63
The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. Cancer Res (2011) 2.60
Lymphotoxin controls the IL-22 protection pathway in gut innate lymphoid cells during mucosal pathogen challenge. Cell Host Microbe (2011) 2.46
Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol (2006) 2.44
CD95 promotes tumour growth. Nature (2010) 2.42
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg (2012) 2.28
Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res (2005) 2.28
Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease. Nat Med (2002) 2.23
Antigen persistence and the control of local T cell memory by migrant respiratory dendritic cells after acute virus infection. J Exp Med (2010) 2.22
Genome-wide screen of promoter methylation identifies novel markers in melanoma. Genome Res (2009) 2.13
Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol (2013) 2.13
Lymphotoxin beta receptor signaling promotes tertiary lymphoid organogenesis in the aorta adventitia of aged ApoE-/- mice. J Exp Med (2009) 2.12
Lymphotoxin beta receptor-dependent control of lipid homeostasis. Science (2007) 2.06
Advances in the systemic treatment of metastatic melanoma. Oncology (Williston Park) (2013) 2.05
Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol (2012) 2.03
Group 3 innate lymphoid cells inhibit T-cell-mediated intestinal inflammation through aryl hydrocarbon receptor signaling and regulation of microflora. Immunity (2013) 2.01
Coordinated epithelial NHE3 inhibition and barrier dysfunction are required for TNF-mediated diarrhea in vivo. J Clin Invest (2006) 2.00
The role of BRAF V600 mutation in melanoma. J Transl Med (2012) 2.00
MicroRNA signatures differentiate melanoma subtypes. Cell Cycle (2011) 1.99
Lymphotoxin regulates commensal responses to enable diet-induced obesity. Nat Immunol (2012) 1.99
Tumor masses support naive T cell infiltration, activation, and differentiation into effectors. J Exp Med (2010) 1.97
The HIF-1α hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy. Cancer Discov (2012) 1.95
B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism. J Exp Med (2003) 1.92
Direct effects of type I interferons on cells of the immune system. Clin Cancer Res (2011) 1.91
Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. J Clin Oncol (2005) 1.88
Dynamic programmed death 1 expression by virus-specific CD8 T cells correlates with the outcome of acute hepatitis B. Gastroenterology (2008) 1.84
The role of herpesvirus entry mediator as a negative regulator of T cell-mediated responses. J Clin Invest (2005) 1.82
Integrative analysis of epigenetic modulation in melanoma cell response to decitabine: clinical implications. PLoS One (2009) 1.80
Lymphotoxin pathway directs thymic Aire expression. Nat Immunol (2003) 1.79
Local expression of B7-H1 promotes organ-specific autoimmunity and transplant rejection. J Clin Invest (2004) 1.71
B cell maintenance of subcapsular sinus macrophages protects against a fatal viral infection independent of adaptive immunity. Immunity (2012) 1.70
LIGHT signals directly to intestinal epithelia to cause barrier dysfunction via cytoskeletal and endocytic mechanisms. Gastroenterology (2007) 1.70
Route of immunization with peptide-pulsed dendritic cells controls the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control. J Exp Med (2003) 1.68
Gemcitabine versus bacille Calmette-Guérin after initial bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial. Cancer (2010) 1.66
The human BCL6 transgene promotes the development of lymphomas in the mouse. Proc Natl Acad Sci U S A (2004) 1.63
B and T lymphocyte attenuator regulates CD8+ T cell-intrinsic homeostasis and memory cell generation. Nat Immunol (2007) 1.61
CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J Immunol (2003) 1.61
Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases. J Immunol (2007) 1.60
Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use. J Transl Med (2012) 1.60
Type I interferon response and innate immune sensing of cancer. Trends Immunol (2012) 1.59
Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort. J Transl Med (2014) 1.59
Phase I and pharmacokinetic study of Triapine, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies. Leuk Res (2007) 1.57
Interaction of mature CD3+CD4+ T cells with dendritic cells triggers the development of tertiary lymphoid structures in the thyroid. J Clin Invest (2006) 1.57
The role of stroma in immune recognition and destruction of well-established solid tumors. Curr Opin Immunol (2006) 1.56
Tumor-infiltrating T lymphocytes: friends or foes? Lab Invest (2006) 1.56
Positioning of follicular dendritic cells within the spleen controls prion neuroinvasion. Nature (2003) 1.51
Lymphotoxin beta receptor signaling in intestinal epithelial cells orchestrates innate immune responses against mucosal bacterial infection. Immunity (2010) 1.50
Complementary role of CD4+ T cells and secondary lymphoid tissues for cross-presentation of tumor antigen to CD8+ T cells. J Exp Med (2003) 1.49
Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of experimental autoimmune encephalomyelitis. J Immunol (2002) 1.45
Radiation-induced equilibrium is a balance between tumor cell proliferation and T cell-mediated killing. J Immunol (2013) 1.44
OX40 signaling favors the induction of T(H)9 cells and airway inflammation. Nat Immunol (2012) 1.43
NK-cell activation by LIGHT triggers tumor-specific CD8+ T-cell immunity to reject established tumors. Blood (2005) 1.43
Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients. Cancer Gene Ther (2003) 1.40
Recruitment and activation of naive T cells in the islets by lymphotoxin beta receptor-dependent tertiary lymphoid structure. Immunity (2006) 1.40
A phase 2 trial of dasatinib in advanced melanoma. Cancer (2010) 1.40
Equilibrium between host and cancer caused by effector T cells killing tumor stroma. Cancer Res (2008) 1.39
Melanoma: a model for testing new agents in combination therapies. J Transl Med (2010) 1.39
Signaling via LTbetaR on the lamina propria stromal cells of the gut is required for IgA production. Nat Immunol (2002) 1.36
Hyper innate responses in neonates lead to increased morbidity and mortality after infection. Proc Natl Acad Sci U S A (2008) 1.33
Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. Sci Transl Med (2014) 1.30
Tumor necrosis factor family members and inflammatory bowel disease. Immunol Rev (2005) 1.29
NF-kappaB2 is required for the establishment of central tolerance through an Aire-dependent pathway. J Clin Invest (2006) 1.29
Targeting CD137 enhances the efficacy of cetuximab. J Clin Invest (2014) 1.29
Dysregulated LIGHT expression on T cells mediates intestinal inflammation and contributes to IgA nephropathy. J Clin Invest (2004) 1.28
Differential regulation of CCL21 in lymphoid/nonlymphoid tissues for effectively attracting T cells to peripheral tissues. J Clin Invest (2003) 1.27
White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy. Clin Cancer Res (2011) 1.27
Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J Clin Oncol (2004) 1.25
SimB16: modeling induced immune system response against B16-melanoma. PLoS One (2011) 1.25
Cetuximab-mediated tumor regression depends on innate and adaptive immune responses. Mol Ther (2012) 1.24
Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors. Clin Cancer Res (2003) 1.24
Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma. Clin Cancer Res (2008) 1.24
TNFR2 activates MLCK-dependent tight junction dysregulation to cause apoptosis-mediated barrier loss and experimental colitis. Gastroenterology (2013) 1.24
Gadd45beta promotes hepatocyte survival during liver regeneration in mice by modulating JNK signaling. J Clin Invest (2008) 1.23
Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes. Cancer Res (2011) 1.23
Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy. Yale J Biol Med (2011) 1.23
The inhibitory HVEM-BTLA pathway counter regulates lymphotoxin receptor signaling to achieve homeostasis of dendritic cells. J Immunol (2008) 1.23